Advanced

Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study.

Steffensen, Karina Dahl; Waldstrøm, Marianne; Pallisgård, Niels; Lund, Bente; Bergfeldt, Kjell LU ; Wihl, Jessica; Keldsen, Nina; Marth, Christian; Vergote, Ignace and Jakobsen, Anders (2013) In International Journal of Gynecological Cancer 23(1). p.73-80
Abstract
OBJECTIVE: The increasing number of negative trials for ovarian cancer treatment has prompted an evaluation of new biologic agents, which in combination with chemotherapy may improve survival. The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab. PATIENTS AND METHODS: Major eligibility criteria were relapsed ovarian/fallopian/peritoneal cancer patients with platinum-resistant disease, measurable disease by GCIG CA125 criteria and KRAS wild-type. Patients were treated with panitumumab 6 mg/kg day 1 and day 15 and with PLD 40 mg/m day 1, every 4 weeks. RESULTS: Forty-six patients were enrolled... (More)
OBJECTIVE: The increasing number of negative trials for ovarian cancer treatment has prompted an evaluation of new biologic agents, which in combination with chemotherapy may improve survival. The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab. PATIENTS AND METHODS: Major eligibility criteria were relapsed ovarian/fallopian/peritoneal cancer patients with platinum-resistant disease, measurable disease by GCIG CA125 criteria and KRAS wild-type. Patients were treated with panitumumab 6 mg/kg day 1 and day 15 and with PLD 40 mg/m day 1, every 4 weeks. RESULTS: Forty-six patients were enrolled by 6 study sites in this multi-institutional phase II trial. The response rate in the intention-to-treat population (n = 43) was 18.6%. Progression-free and overall survival in the intention-to-treat population was 2.7 months (2.5-3.2 months, 95% confidence interval) and 8.1 months (5.6-11.7 months, 95% confidence interval), respectively. The most common treatment-related grade 3 toxicities included skin toxicity (42%), fatigue (19%), and vomiting (12%). CONCLUSIONS: The combination of PLD and panitumumab demonstrates efficacy in platinum refractory/resistant patients but the skin toxicity was considerable. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
resistance, Platinum, Liposomal doxorubicin, EGFR inhibition, Ovarian cancer, KRAS
in
International Journal of Gynecological Cancer
volume
23
issue
1
pages
73 - 80
publisher
Wiley-Blackwell
external identifiers
  • wos:000314005000011
  • pmid:23211422
  • scopus:84872309752
ISSN
1048-891X
DOI
10.1097/IGC.0b013e3182775fae
language
English
LU publication?
yes
id
1ed27932-5c3b-4c6c-9d85-a64974223fb0 (old id 3347635)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23211422?dopt=Abstract
date added to LUP
2013-01-02 12:16:25
date last changed
2019-03-19 01:10:46
@article{1ed27932-5c3b-4c6c-9d85-a64974223fb0,
  abstract     = {OBJECTIVE: The increasing number of negative trials for ovarian cancer treatment has prompted an evaluation of new biologic agents, which in combination with chemotherapy may improve survival. The aim of this study was to investigate the response rate in platinum-resistant, KRAS wild-type ovarian cancer patients treated with pegylated liposomal doxorubicin (PLD) supplemented with panitumumab. PATIENTS AND METHODS: Major eligibility criteria were relapsed ovarian/fallopian/peritoneal cancer patients with platinum-resistant disease, measurable disease by GCIG CA125 criteria and KRAS wild-type. Patients were treated with panitumumab 6 mg/kg day 1 and day 15 and with PLD 40 mg/m day 1, every 4 weeks. RESULTS: Forty-six patients were enrolled by 6 study sites in this multi-institutional phase II trial. The response rate in the intention-to-treat population (n = 43) was 18.6%. Progression-free and overall survival in the intention-to-treat population was 2.7 months (2.5-3.2 months, 95% confidence interval) and 8.1 months (5.6-11.7 months, 95% confidence interval), respectively. The most common treatment-related grade 3 toxicities included skin toxicity (42%), fatigue (19%), and vomiting (12%). CONCLUSIONS: The combination of PLD and panitumumab demonstrates efficacy in platinum refractory/resistant patients but the skin toxicity was considerable.},
  author       = {Steffensen, Karina Dahl and Waldstrøm, Marianne and Pallisgård, Niels and Lund, Bente and Bergfeldt, Kjell and Wihl, Jessica and Keldsen, Nina and Marth, Christian and Vergote, Ignace and Jakobsen, Anders},
  issn         = {1048-891X},
  keyword      = {resistance,Platinum,Liposomal doxorubicin,EGFR inhibition,Ovarian cancer,KRAS},
  language     = {eng},
  number       = {1},
  pages        = {73--80},
  publisher    = {Wiley-Blackwell},
  series       = {International Journal of Gynecological Cancer},
  title        = {Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study.},
  url          = {http://dx.doi.org/10.1097/IGC.0b013e3182775fae},
  volume       = {23},
  year         = {2013},
}